At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled, Multi National, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablet, Starting 2 Months Before the Grass Pollen Season Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis
In Brief
A Phase 3 clinical trial evaluating 300 IR and Placebo for Primary Disease. Completed, enrolled 381 participants across 6 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of sublingual tablets of grass pollen allergen extract when initiated 2 months before the grass pollen season compared with placebo for reduction of rhinoconjunctivitis symptoms and rescue medication usage.
Study Details
Timeline
Interventions
300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season
Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season